Jun 25, 2026 4:15 pm EDT Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Jun 23, 2026 9:57 pm EDT Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
Jun 22, 2026 7:00 am EDT Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
Jun 21, 2026 5:00 pm EDT Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
May 21, 2026 7:00 am EDT Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 12, 2026 7:00 am EDT Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder